ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The initial dependence of CML on the expression of BCR-ABL has led to the development of a number of ABL tyrosine kinase inhibitors (TKIs), with such TKIs now representing the front-line therapy for CML patients.